AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03968640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
Study NCT03968640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
Study NCT00446680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 400mg BD for 6 months followed by a 6 month open label period
Study NCT00446680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BD for 6 months
Study NCT04621383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein plus collagen
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study NCT04621383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein plus maltodextrin
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study NCT00927914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranirestat
Description: Ranirestat 40 mg tablets
Study NCT00927914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT00927914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study NCT02375061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-BPS
Study NCT02375061 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Study NCT01437475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac
Description: 10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
Study NCT02051933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U
Study NCT02051933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U
Study NCT00550641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy in warm pool performing stretching
Study NCT00550641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: physical therapy in warm pool performing Ai Chi
Study NCT04561726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation
Description: Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
Study NCT04561726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
Study NCT04561726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
Study NCT01779817 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
Study NCT00921895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPS Adeno Detector IV
Description: One time test with the RPS Adeno Detector IV
Study NCT00581880 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
Study NCT00391209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals,6 months
Study NCT00391209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 6 months
Study NCT01934647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
Study NCT00724711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
Description: FTC 200 mg/TDF 300 mg tablet, once a day
Study NCT00724711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir (ABC)/lamivudine (3TC)
Description: ABC 600 mg/3TC 300 mg tablet, once a day
Study NCT05576545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Breast Cancer Self-Care App
Description: The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
Study NCT03976622 — intervention group
Intervention type: BIOLOGICAL
Intervention: Skin biopsies
Description: These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Study NCT02044107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-packaging and counseling messages
Description: The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
Study NCT03496779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin - induction
Description: Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
Study NCT03496779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
Study NCT01469559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolin Toronto insulin
Description: Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
Study NCT01469559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
Study NCT03246100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
Study NCT02393157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
Study NCT03496779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin - maintenance
Description: Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy
Study NCT03496779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous or allogeneic stem cell transplantation
Description: Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
Study NCT02199899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIF 1149 BS - single rising doses
Study NCT02199899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
Study NCT00974584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
Study NCT06199583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear-wave elastography
Description: Ultrasound shear-wave elastography
Study NCT01168219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation
Study NCT01168219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT01168219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT01275209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study NCT01168219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01168219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01168219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01168219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01168219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01168219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV
Study NCT02872844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICS AirCal3
Description: Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
Study NCT00533793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open fracture reduction
Description: internal fracture fixation: osteosynthesis plates or intra-medullary nails
Study NCT02816827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-01
Description: Product to increase mental alertness
Study NCT03122431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: Thalidomide 100 mg/day
Study NCT03122431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine reduced
Description: Hydroxychloroquine 2.5 mg/kg/day
Study NCT03122431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose of HCQ
Description: Hydroxychloroquine 5.0 mg/kg/day
Study NCT02816827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-05
Description: Product to increase mental alertness
Study NCT02816827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-06
Description: Product to increase mental alertness
Study NCT02816827 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG-07
Description: Product to increase mental alertness
Study NCT01385397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preceptorship and virtual community
Study NCT02245425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine Thoracic Spine Manipulation
Description: Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study NCT02245425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone Thoracic Spine Manipulation
Description: Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study NCT01811056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone use outside of the center
Study NCT02575547 — intervention group
Intervention type: DRUG
Intervention: cisplatin and docetaxel
Description: NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition
Study NCT03154229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone-based decision-support
Description: WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
Study NCT03154229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based decision-support
Description: WHO guidelines presented on paper
Study NCT03154229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Assessment of practices
Description: Observation of baseline clinical practice.
Study NCT00458029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated program of nutrition, activity, behavior, and promotion
Description: implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Aromatase inhibitor
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Aromatase inhibitor
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Luteinizing Hormone-Releasing Hormone agonist
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Monoclonal antibody (HER2/neu receptor antagonist)
Study NCT02689921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal antibody (HER2/neu receptor antagonist)
Study NCT03968939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine (Benadryl)
Description: Oral Diphenhydramine (Benadryl), 25 mg
Study NCT03968939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral Melatonin, 3 mg
Study NCT03968939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Brochure containing information about getting a good night's sleep.